February 2014 Issue Table Of Contents

From The Editor

• Reports Of U.S. Biomedical R&D Demise – A Great Exaggeration

Capitol Perspectives

• CMS Guts Patient Protection In Part D

Companies To Watch

• Companies To Watch: A Roundup Of Life Science Developments And Technologies

Outsourcing Insights

• As Biologics Development Rises At Pharma Companies – What Does It Mean For Outsourcing?

Bio Innovation notes

• In Continuous Bioprocessing Wider Adoption Signals Industry Maturation

Feature

• Lilly’s Approach To The Clinical Trial Paradox
• Janet Woodcock’s Quality Agenda At CDER

Inside The Industry

• Leadership By Fear – Falling Off The Tiger
• How To Launch A Biotech Start-Up
• Surfing The Peaks And Troughs Of The Biotech Ocean
• Technology Considerations To Increasing Clinical Trial Efficiencies With Risk-Based Monitoring
• EU Sets The Stage For Increased Pharmacovigilance Oversight And Harmonization

Ask The Board

• Ask The Board